APPLIED GENETIC TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2019-12-09: Form 8-K; Period of report 2019-12-04; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2019-12-02: Form 8-K; Period of report 2019-11-27; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
- 2019-11-12: Form 8-K; Period of report 2019-11-12; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2019-09-26: Form 8-K; Period of report 2019-09-26; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2019-12-09 | 8-K | 2019-12-04 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 We held our 2020 Annual Meeting of Stockholders on December 4, 2019, at which four proposals were submitted to, and approved by, our stockholders. | d766002d8k.htm |
| 2019-12-02 | 8-K | 2019-11-27 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On December 2, 2019, Applied Genetic Technologies Corporation (the “Company”) issued a press release regarding the resignation of Theresa Heah, MD, MBA as the Company’s Chief Medical Officer. 8.01 On November 27, 2019, Theresa Heah, MD, MBA notified the Company of her resignation as Chief Medical Officer effective December 31, 2019. | d822680d8k.htm |
| 2019-11-12 | 8-K | 2019-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2019, Applied Genetic Technologies Corporation issued a press release entitled “AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2019.” The press release is furnished as Exhibit 99.1. | d789251d8k.htm |
| 2019-09-26 | 8-K | 2019-09-26 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On September 26, 2019, Applied Genetic Technologies Corporation (the “Company”) issued a press release entitled “AGTC Announces Financial Results and Business Update for the Fourth Quarter and Fiscal Year Ended June 30, 2019.” The press release is furnished as Exhibit 99.1. 7.01 The Company will present during its earnings call on September 26, 2019 a summary of recent corporate and clinical developments. | d811598d8k.htm |
| 2019-08-02 | 8-K | 2019-07-29 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 29, 2019, Applied Genetic Technologies Corporation (the “Company”) entered into an employment letter agreement (the “Employment Agreement”) with Dr. Matthew Feinsod pursuant to which Dr. Feinsod agreed to serve as the Company’s Executive Vice President of Global Strategy and Development effective on August 1, 2019 in connection with the hiring of Dr. Theresa Heah as the Company’s Chief Medical Officer (as previously disclosed in a Current Report on Form 8-K filed by the Company on June 25, 2019). | d784873d8k.htm |
| 2019-07-26 | 8-K | 2019-07-23 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 23, 2019, the compensation committee of our board of directors approved bonus payments for fiscal year 2019 and salary changes for fiscal year 2020 for Susan Washer, our president and chief executive officer, Mark Shearman, our chief scientific officer, William Sullivan, our chief financial officer, Stephen Potter, our vice president and chief business officer, and Brian Krex, our general counsel (bonus prorated for period employed during fiscal year 2019). | d760323d8k.htm |
| 2019-06-25 | 8-K | 2019-06-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On June 19, 2019, Applied Genetic Technologies Corporation (the “Company”) notified Dr. Feinsod that, in connection with Dr. Theresa Heah joining the Company as Chief Medical Officer (as disclosed in Item7.01 below), the Company does not intend to renew the term of his at-will employment letter as interim Chief Medical Officer. 7.01 On June 25, 2019, the Company announced the appointment of Theresa Heah, MD, MBA as Chief Medical Officer, effective July 29, 2019, and the prior appointment of Brian Krex as General Counsel. | d771708d8k.htm |
| 2019-05-07 | 8-K | 2019-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2019, Applied Genetic Technologies Corporation issued a press release entitled “AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019.” The earnings release is furnished herewith as Exhibit 99.1. | d742079d8k.htm |
| 2019-02-07 | 8-K | 2019-02-07 | 2.02 Results of Operations and Financial Condition | 2.02 On February 7, 2019, Applied Genetic Technologies Corporation issued a press release entitled “AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2018.” The earnings release is furnished herewith as Exhibit 99.1. | d704690d8k.htm |